News
On an earnings call in February, he answered question after question about plunging demand for his company’s vaccine against ...
Investor's Business Daily on MSN1d
Gardasil Sales Decline — Again. Can Dow Jones Stock Merck Take The Hit?Merck stock could take another hit Thursday after the company reported another quarter of light sales for its HPV vaccine, ...
Proquad is rarely a newsmaker from Merck’s earnings, but this time around, the U.S. has had a series of measles outbreaks.
Merck maintained its 2025 full-year revenue guidance of $64.1 billion to $65.6 billion, representing 1% to 3% growth excluding foreign exchange impacts. EPS guidance was adjusted to $8.82 to $8.97, ...
GARDASIL 9 is a vaccine that helps protect against disease caused by the following types of Human Papillomavirus (HPV): 6, 11, 16, 18, 31, 33, 45, 52 and 58. For more information, see Section 1.
NEW YORK, NY / ACCESS Newswire / April 14, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...
SEATTLE — Since its approval by the U.S. Food and Drug Administration in 2006, the HPV vaccine has made considerable strides in preventing cervical and oropharyngeal, or throat cancers.
In the last two years, Merck has beaten EPS estimates 88% of the time, and revenue estimates 100% of the time. Meanwhile, ...
On July 30, 2024, Merck released its second quarter 2024 financial report and disclosed a significant reduction in Gardasil vaccinations, resulting in an overabundance of inventory at Merck's Chinese ...
GlobalData on MSN1d
MSD’s Gardasil sales slide further due to China constraintsMSD is also bracing for a $200m hit due to tariffs as it accelerates US manufacturing and shifts its global supply strategy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback